United States Genetic Testing Market

The United States genetic testing market growth is anticipated to progress at a CAGR of 10.61% during the forecast period, 2022-2028, reaching a revenue of $8596.6 million by 2028.

UNITED STATES GENETIC TESTING MARKET FORECAST 2022-2028

United States Genetic Testing Market by Type (Prenatal and Newborn Testing, Diagnostic Testing, Predictive & Pre symptomatic Testing, Carrier Testing, Pharmacogenomic Testing, Other Types) Market by Technology (Molecular Testing, Cytogenetic Testing, Biochemical Testing) Market by Application (Genetic Disease Diagnosis, Cancer Diagnosis, Cardiovascular Disease Diagnosis, Other Applications) Market by Disease (Cancer, Cystic Fibrosis, Huntington’s Disease, Sickle Cell Anaemia, Duchenne Muscular Dystrophy, Alzheimer’s Disease, Rare Diseases, Thalassemia, Other Diseases)

Request free sample

The United States genetic testing market growth is anticipated to progress at a CAGR of 10.61% during the forecast period, 2022-2028, reaching a revenue of $8596.6 million by 2028.

There is increased adoption of genetic testing, given its vast applications in the healthcare sector. For instance, it covers chronic diseases like cancer, genetic diseases, and cardiovascular conditions. Also, with large healthcare expenditure, the growing population prefers such testing procedures. Besides, there is an increasing need and awareness about early and preventive care.

United States Genetic Testing Market

To know more about this report, request a free sample copy

In the United States, a steady increase in the insurance coverage of varied genetic tests by key insurance companies is a significant trend impacting the market growth. Also, the rising economic burden associated with disease treatment has led to governing bodies and healthcare providers increasingly prioritizing early screening and diagnosis for health risks.

Genetic tests are used for detecting serious medical problems and diseases. As a result, such tests have become an essential part of preventive care since most private healthcare players are incorporating them into the reimbursement policies. Besides, a large number of people are opting for such testing procedures for rare genetic disorders.

Furthermore, genomic and genetic testing are expanding across different medical specialties, resulting in strong testing volume managed by non-geneticists. Moreover, the technological advancements to enhance testing accuracy offer growth opportunities. Also, the US has economic advantages and increased funding with regard to research and production of innovative medical devices.

The United States genetic testing market report scope includes the segmentation assessment of application, disease, type, and technology. The type segment is further sub-categorized into Prenatal and newborn testing, diagnostic testing, predictive & presymptomatic testing, pharmacogenomic testing, carrier testing, and other types.

Carrier testing is evaluated to project promising growth during the forecast period. It is a genetic test for determining whether a person is a carrier of the recessive genetic disease. It is a disease caused due to mutation on both genes of a pair. As a result, if both parents are carriers, they have a 25% risk of having a child with recessive genetic disease. In addition, there is also a 50% risk that the child will be a carrier.

Further, diagnostic testing is expected to garner more revenue share during the forecast period. It is used to rule out or identify a specific chromosomal or genetic condition. At the same time, it is utilized to confirm a diagnosis when a certain condition is evaluated based on physical symptoms. It can be conducted before birth or any time during a person’s life but has limited coverage for genetic conditions. The results can be vital in early disease diagnosis and minimizing major health crises. Moreover, it can help patients implement informed decisions and incorporate lifestyle changes that can likely restrict the disease’s magnitude.

Some of the eminent market players in the United States genetic testing market include PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories, Myriad Genetics Inc, etc.

Illumina Inc offers array-based and sequencing solutions for genomic and genetic analysis. It markets and distributes its products directly to consumers in Asia-Pacific, Latin America, Europe, and North America. It also offers consumables and instruments used in genotyping & sequencing services, genetic analysis, development & licensing agreements, and instrument service contracts. It caters to academic institutions, genomic research centers, hospitals, government laboratories, consumer genomics companies, commercial molecular diagnostic laboratories, etc. It is headquartered in San Diego, California.

One of its key products, RNA prep enrichment, helps achieve rapid interrogation of an expansive number of target genes that include the RNA exome.

Report Synopsis

Report Scope Details
Market Forecast Years 2022-2028
Base Year 2021
Market Historical Years 2018-2021
Forecast Units Revenue ($ Million)
Segments Analyzed Application, Disease, Type, Technology
Companies Analyzed

Abbott Laboratories, Bio-Rad Laboratories, Myriad Genetics Inc, Illumina Inc, PerkinElmer Inc

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • COUNTRY SNAPSHOT
      • COUNTRY ANALYSIS
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
    3. KEY ANALYTICS
      • IMPACT OF COVID-19 ON GENETIC TESTING MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • VALUE CHAIN ANALYSIS
      • KEY BUYING CRITERIA
      • REGULATORY FRAMEWORK
    4. MARKET BY TYPE
      • PRENATAL AND NEWBORN TESTING
      • DIAGNOSTIC TESTING
      • PREDICTIVE & PRESYMPTOMATIC TESTING
      • CARRIER TESTING
      • PHARMACOGENOMIC TESTING
      • OTHER TYPES
    5. MARKET BY TECHNOLOGY
      • MOLECULAR TESTING
      • CYTOGENETIC TESTING
      • BIOCHEMICAL TESTING
    6. MARKET BY APPLICATION
      • GENETIC DISEASE DIAGNOSIS
      • CANCER DIAGNOSIS
      • CARDIOVASCULAR DISEASE DIAGNOSIS
      • OTHER APPLICATIONS
    7. MARKET BY DISEASE
      • CANCER
      • CYSTIC FIBROSIS
      • HUNTINGTON’S DISEASE
      • SICKLE CELL ANAEMIA
      • DUCHENNE MUSCULAR DYSTROPHY
      • ALZHEIMER’S DISEASE
      • RARE DISEASE
      • THALASSEMIA
      • OTHER DISEASES
    8. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS & DIVESTITURES
      • COMPANY PROFILES
        • ABBOTT LABORATORIES
        • BIORAD LABORATORIES
        • ILLUMINA INC
        • MYRIAD GENETICS INC
        • PERKINELMER INC

    LIST OF TABLES

    TABLE 1: COUNTRY SNAPSHOT – GENETIC TESTING

    TABLE 2: REGULATORY FRAMEWORK

    TABLE 3: UNITED STATES GENETIC TESTING MARKET, BY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 4: UNITED STATES GENETIC TESTING MARKET, BY TYPE, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 5: UNITED STATES GENETIC TESTING MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 6: UNITED STATES GENETIC TESTING MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 7: UNITED STATES GENETIC TESTING MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 8: UNITED STATES GENETIC TESTING MARKET, BY APPLICATION, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 9: UNITED STATES GENETIC TESTING MARKET, BY DISEASE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 10: UNITED STATES GENETIC TESTING MARKET, BY DISEASE, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 11: LEADING PLAYERS OPERATING IN UNITED STATES GENETIC TESTING MARKET

    TABLE 12: LIST OF MERGERS & ACQUISITIONS

    TABLE 13: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 14: LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 15: LIST OF BUSINESS EXPANSIONS & DIVESTITURES                           

    LIST OF FIGURES

    FIGURE 1: KEY MARKET TRENDS

    FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: VALUE CHAIN ANALYSIS

    FIGURE 6: UNITED STATES GENETIC TESTING MARKET, GROWTH POTENTIAL, BY TYPE, IN 2021

    FIGURE 7: UNITED STATES GENETIC TESTING MARKET, BY PRENATAL AND NEWBORN TESTING GENETIC TESTING, 2022-2028 (IN $ MILLION)

    FIGURE 8: UNITED STATES GENETIC TESTING MARKET, BY DIAGNOSTIC TESTING, 2022-2028 (IN $ MILLION)

    FIGURE 9: UNITED STATES GENETIC TESTING MARKET, BY CARRIER TESTING, 2022-2028 (IN $ MILLION)

    FIGURE 10: UNITED STATES GENETIC TESTING MARKET, BY PHARMACOGENOMIC TESTING, 2022-2028 (IN $ MILLION)

    FIGURE 11: UNITED STATES GENETIC TESTING MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021

    FIGURE 12: UNITED STATES GENETIC TESTING MARKET, BY MOLECULAR TESTING, 2022-2028 (IN $ MILLION)

    FIGURE 13: UNITED STATES GENETIC TESTING MARKET, BY CYTOGENETIC TESTING, 2022-2028 (IN $ MILLION)

    FIGURE 14: UNITED STATES GENETIC TESTING MARKET, BY BIOCHEMICAL TESTING, 2022-2028 (IN $ MILLION)

    FIGURE 15: UNITED STATES GENETIC TESTING MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

    FIGURE 16: UNITED STATES GENETIC TESTING MARKET, BY GENETIC DISEASE DIAGNOSIS, 2022-2028 (IN $ MILLION)

    FIGURE 17: UNITED STATES GENETIC TESTING MARKET, BY CANCER DIAGNOSIS, 2022-2028 (IN $ MILLION)

    FIGURE 18: UNITED STATES GENETIC TESTING MARKET, BY CARDIOVASCULAR DISEASES DIAGNOSIS, 2022-2028 (IN $ MILLION)

    FIGURE 19: UNITED STATES GENETIC TESTING MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

    FIGURE 20: UNITED STATES GENETIC TESTING MARKET, GROWTH POTENTIAL, BY DISEASE, IN 2021

    FIGURE 21: UNITED STATES GENETIC TESTING MARKET, BY CANCER, 2022-2028 (IN $ MILLION)

    FIGURE 22: UNITED STATES GENETIC TESTING MARKET, BY CYSTIC FIBROSIS, 2022-2028 (IN $ MILLION)

    FIGURE 23: UNITED STATES GENETIC TESTING MARKET, BY HUNTINGTON’S DISEASE, 2022-2028 (IN $ MILLION)

    FIGURE 24: UNITED STATES GENETIC TESTING MARKET, SICKLE CELL ANEMIA, 2022-2028 (IN $ MILLION)

    FIGURE 25: UNITED STATES GENETIC TESTING MARKET, BY DUCHENNE MUSCULAR DYSTROPHY, 2022-2028 (IN $ MILLION)

    FIGURE 26: UNITED STATES GENETIC TESTING MARKET, BY ALZHEIMER’S DISEASE, 2022-2028 (IN $ MILLION)

    FIGURE 27: UNITED STATES GENETIC TESTING MARKET, BY RARE DISEASES, 2022-2028 (IN $ MILLION)

    FIGURE 28: UNITED STATES GENETIC TESTING MARKET, BY THALASSEMIA, 2022-2028 (IN $ MILLION)

    FIGURE 29: UNITED STATES GENETIC TESTING MARKET, BY OTHER DISEASES, 2022-2028 (IN $ MILLION)       

    1. MARKET BY TYPE
      • PRENATAL AND NEWBORN TESTING
      • DIAGNOSTIC TESTING
      • PREDICTIVE & PRESYMPTOMATIC TESTING
      • CARRIER TESTING
      • PHARMACOGENOMIC TESTING
      • OTHER TYPES
    2. MARKET BY TECHNOLOGY
      • MOLECULAR TESTING
      • CYTOGENETIC TESTING
      • BIOCHEMICAL TESTING
    3. MARKET BY APPLICATION
      • GENETIC DISEASE DIAGNOSIS
      • CANCER DIAGNOSIS
      • CARDIOVASCULAR DISEASE DIAGNOSIS
      • OTHER APPLICATIONS
    4. MARKET BY DISEASE
      • CANCER
      • CYSTIC FIBROSIS
      • HUNTINGTON’S DISEASE
      • SICKLE CELL ANAEMIA
      • DUCHENNE MUSCULAR DYSTROPHY
      • ALZHEIMER’S DISEASE
      • RARE DISEASE
      • THALASSEMIA
      • OTHER DISEASES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type